Trial reportMedicinal chemistry (Shariqah (United Arab Emirates))2015
Practical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes.
Trial report in Medicinal chemistry (Shariqah (United Arab Emirates)), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.Pharmaceutical biology · 2024Pooled it
- Cardiovascular disease risk reduction with wolfberry consumption: a systematic review and meta-analysis of randomized controlled trials.European journal of nutrition · 2022Pooled it
- A Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease.BioMed research international · 2019Pooled it
- Quality Evaluation and Multi-Criteria Optimization of Cookies Fortified with Lyophilized Black Goji.Foods (Basel, Switzerland) · 2026Article
- Structural-activity relationship ofFrontiers in immunology · 2026Review
- Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges.Frontiers in immunology · 2026Review
- Comprehensive Review on the Protective Effects of Lycium barbarum Polysaccharide on Neurodegenerative DiseasesEndocrine, metabolic & immune disorders drug targets · 2026Review
- Fermented Food-Polysaccharides as Gut Health Regulators: Sources, Optimization, Structural Characteristics and Mechanism.Foods (Basel, Switzerland) · 2025Review
- A fibrin gel-loaded Gouqi-derived nanovesicle (GqDNV) repairs the heart after myocardial infarction by inhibiting p38 MAPK/NF-κB p65 pathway.Journal of nanobiotechnology · 2025Article
- Review
- Edible Berries-An Update on Nutritional Composition and Health Benefits-Part II.Current nutrition reports · 2025Review
- Superfoods in Drug Discovery: Nutrient Profiles and their Emerging Health Benefits.Current drug discovery technologies · 2025Review
- Therapeutic potential ofFrontiers in nutrition · 2025Review
- Recent advances in natural polysaccharides for type 2 diabetes management: sources, structural characteristics, and mechanistic insights.Frontiers in pharmacology · 2025Review
- Regulatory effects ofFrontiers in immunology · 2025Review
- The roles and potential mechanisms of plant polysaccharides in liver diseases: a review.Frontiers in pharmacology · 2024Review
- Nourishing Yin traditional Chinese medicine: potential role in the prevention and treatment of type 2 diabetes.American journal of translational research · 2024Review
- Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lycium barbarum polysaccharide (LBP) has traditionally been used in Chinese medicine as a chief ingredient of Lycium barbarum (wolf berry/goji berry) for the treatment of various diseases with the symptoms of frequent drinking and urination. This study was conducted as a randomized, controlled clinical trial. A total of 67 patients with type 2 diabetes (30 in control group and 37 in LBP group) were enrolled in this prospective, randomized, double-blind study (administration at 300 mg/day body weight). In order to observe the hypoglycemic and lipid-lowering activity of LBP in patients with type 2 diabetes after dinner, various tests were conducted between control and LBP intervention groups in 3 months. Although, the study had small sample size and short follow-up, significant findings were observed. The results of our study indicated a remarkable protective effect of LBP in patients with type 2 diabetes. Serum glucose was found to be significantly decreased and insulinogenic index increased during OMTT after 3 months administration of LBP. LBP also increased HDL levels in patients with type 2 diabetes. It showed more obvious hypoglycemic efficacy for those people who did not take any hypoglycemic medicine compared to patients taking hypoglycemic medicines. This study showed LBP to be a good potential treatment aided-agent for type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.